These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17667747)

  • 1. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
    Niederkohr RD; Rosenberg J; Shabo G; Quon A
    Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
    Tan JC; Chatterton BE
    Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
    Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
    Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
    Kawata S; Imaizumi M; Kako Y; Oku N
    Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
    Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
    Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of whole-body (head-to-toe) PET/CT in the evaluation of melanoma and sarcoma patients.
    Webb HR; Latifi HR; Griffeth LK
    Nucl Med Commun; 2018 Jan; 39(1):68-73. PubMed ID: 29189489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
    Plouznikoff N; Arsenault F
    Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
    Osman MM; Chaar BT; Muzaffar R; Oliver D; Reimers HJ; Walz B; Nguyen NC
    AJR Am J Roentgenol; 2010 Dec; 195(6):1397-403. PubMed ID: 21098201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
    Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
    Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Body versus Routine Skull Base to Mid-thigh
    Ozdemir S; McCook B; Klassen C
    J Clin Imaging Sci; 2020; 10():47. PubMed ID: 32874752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
    Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients.
    Römer W; Nömayr A; Greess H; Fiedler E; Platsch G; Schuler-Thurner B; Pfahlberg A; Hothorn T; Schuler G; Hornegger J; Bautz W; Kuwert T
    Nuklearmedizin; 2006; 45(2):88-95. PubMed ID: 16547570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
    Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
    Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of whole body
    Bower N; Morris A; O'Connor J; Sponagle M; Bahr R; Gilbert R; Mohamed A; Bower J
    J Med Imaging Radiat Sci; 2024 Jun; 55(2):212-220. PubMed ID: 38403520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
    Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
    Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.